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Background:  Kenya is a high HIV/AIDS prevalence country and the epidemic has been declared a national 
disaster, and is at top of the government’s agenda.    
Objective:  To determine the prevalence of HIV infection among suspected tuberculosis (TB) cases seeking 
healthcare at chest and paediatric clinics in Western Kenya.   
Methods:  This cross-sectional study was done between 2007 and 2009.  A total of 695 suspected TB cases (388 
males and 312 females) were screened for HIV infection using Trinity Biotech Uni-GoldTM test and positives 
confirmed with the enzyme linked immunosorbent assay.  A questionnaire was used to collect demographic 
data of the participants.   
Results: In total, 272 (39.1%) of the suspects were HIV infected 50.7% females and 48.3% males.  Females 
were significantly affected than males [OR = 0.69; 95% CI: 0.51-0.94; P = 0.02].  The majority (39.3%) of the 
HIV cases were in the 25-34 age-group followed by the 35-44 (24.6%) and 15-24 (15.8%) age-groups 
respectively.  Only 16.9% of HIV-infected cases were on antiretroviral therapy.   
Conclusions:  The prevalence of HIV infection among suspected TB cases was 39.1%, which was relatively 
lower than 48%, 45% and 44% prevalence rates reported by Division of Leprosy Tuberculosis and Lung 
Disease (DLTLD) in the annual reports of 2007, 2008 and 2009, respectively.  However, it was much higher the 
current national average HIV prevalence of 7.2%.  
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Introduction 
Human Immunodeficiency Virus (HIV) is one of the 
world’s leading cause morbidity and mortality [1].  The 
HIV spreads silently and unnoticed before it wreaks 
havoc and devastation; HIV/AIDS kills people, tears 
apart families, destabilizes communities, slows 
economies, disrupts social services, and weakens 
democracies.  It has a cross-generational impact, 
denying many children their parents’ guard, guidance, 
protection and love [2].  The global HIV morbidity at 
the end of 2009 stood at 33.4 million people, with more 
than 95% of them being in developing countries [1].  
Sub-Saharan Africa, the epicentre of the global 
pandemic remains the region with highest burden, 
accounting for over two thirds, (67%) of the people 
living with HIV and for 72% of HIV/AIDS related 
deaths (UNAIDS and WHO, 2009).  An estimated 1.9 
million people were newly infected with HIV in sub-
Saharan Africa in 2008, bringing to 22.4 million the 
number of people living with HIV in this region.  By 
2008, more than 14 million children in sub-Saharan 
Africa had lost one or both parents to HIV/AIDS 
[3].Although men basically drive the pandemic, 
women and girls make 60 % of those infected in sub-
African, with an average of three women infected for 
every one man [3].  The ratios are even more lop-sided 
between the sexes for the 15-24 age-groups, where 76 
% of the infected are women.  Some population-based 
studies indicate that on average 36 women in this age-
group are living with HIV for every 10 infected young 
men [4].  Young people remain at the heart of the 
disease’s effects, yet all too often at the periphery of 
the world’s response.  Almost every minute of every 
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day, another two young people are infected with HIV. 
Young women remain particularly vulnerable to HIV; 
of the 5.5 million young people aged 15–24 with HIV, 
about two thirds are female [5]. Kenya has also been 
hard-hit by the HIV/AIDS pandemic, which reduced 
live expectancy from 60 years in 1990 to 45.5 years in 
2002.  More than 1.5 million Kenyans live with 
HIV/AIDS [6], the adult prevalence currently standing 
at 7.2 % down from 13 % three years ago.  About 59 % 
of the HIV cases in Kenya are women [6].  However, 
the prevalence is higher (about 20%) among girls and 
young women who are more vulnerable to infection 
[3].  On overage, 71,000 Kenyans die annually from 
HIV/AIDS and related conditions, and on average 
almost every minute 2 people are infected [7].  This 
study was carried out to determine HIV infection rate 
among healthcare seekers at the chest and paediatric 
clinics in Western Kenya.    
 
Materials and methods 
Study Design:  A cross-sectional study was conducted 
between September 2007 and September 2009.  
 
Study site and population:  The study was done at 
chest and paediatric clinics at one provincial and nine 
district hospitals in western Kenya.  These were Busia, 
Bungoma, Kisumu, Migori, Kisii, Narok, Kericho, 
Uasin Gishu and Lodwar district hospitals, and Nakuru 
Provincial General Hospital.  Western Kenya includes 
the expansive former Rift Valley, Nyanza and Western 
Provinces, with a cumulative population of about 19.8 
million people.  This constitutes about 52.1% of the 
Kenyan population. 
  
Sampling frame and patient characteristics:  
Participants suspected of having TB were included at 
random if they sought healthcare services at the chest 
and paediatric clinic between September 2007 and 
September 2009.  They had to be resident in western 
Kenya for at least six months and consented to 
participate in the study.   
 
Collection of demographic data:  A questionnaire 
was used to obtain participant demographic data.  Data 
collected included age, gender, previous anti-TB 
treatment, HIV status, and antiretroviral therapy 
(ART). 
 
Collection of blood samples:  A total of 695 out of the 
872 participants consented phlebotomy for HIV 
testing.  The blood was delivered into Vacutainer 
Brand STERILE interior EDTA (K3) tubes and stored 
at –20oC awaiting processing.  The samples were 
transported in cool boxes to Moi Reference Laboratory 
(MRL), Moi University School of Medicine 
(MUSOM), Eldoret, and processed within two weeks.   
 
HIV testing:  Screening for HIV infection was done by 
screening serum/plasma by the Trinity Biotech Uni-
GoldTM [8] test and positives confirmed with the 
enzyme linked immunosorbent assay [9]. 
 
Data analysis:  Data was entered in MS Excel 8.0 and 
analysed using Epi Info version 3.5.1.  Descriptive 
statistics were used to summarize data and proportions 
compared using chi-square (²) testing.  Univariate 
odds rations (OR) with 95% confidence intervals (CI) 
were calculated to assess risk factors (gender and age-
group) with regard to HIV infection.  Logistic 
regression was used to analyze multivariate data.  
 
Ethical issues 
The proposal for this study was approved by Institute 
of Tropical Medicine and Infectious Diseases 
(ITROMID) / Kenya Medical Research Institute 
(KEMRI)’s Scientific Steering Committee (SSC) and 
Ethical Review Committee (ERC).  It was also 
approved by Moi University School of Medicine (MU-
SOM) / Moi Teaching and Referral Hospital (MTRH) 
Institutional Research and Ethics Committee (IREC).  
Clearance was also obtained from respective district 
health authorities and hospital administrations.  
Informed consent was obtained from candidates or 
their guardians before they were enrolled into the 
study.  The purpose of the study was explained to the 
candidates in English, Kiswahili or local language 
before consent was sought.  Code numbers rather than 
names were used to identify candidates in order to 
maintain confidentiality.  The study did not expose 
candidates to any unusual risks as competent hospital 
staff obtained sputum and blood specimens from 
candidates using standard procedures. 
 
Results 
A total of 872 participants suspected of having TB 
were enrolled into the study at the 10 study sites, 
54.9% (477) males and 45.1% (393) females.  Their 
ages were between 9 months and 80 years, the median 
age being 32 years.  The majority (33.1%) of the 
participants were in the 25-34 age-group, followed by 
those in the 35-44 (21.8%) and 15-24 (18.7%) age-
groups respectively.  Paediatric cases (0-14 age-group) 
were the lowest with 4.6%, with children 5 years and 
below contributing 0.6% (Table 1) 
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Table 1:Study population and gender-age distribution 
Age-group N (%) Males (%) Females (%) 
0-14 39(4.5) 22(2.5) 18(2.1) 
15-24 163(18.7) 80(9.2)  83(9.5) 
25-34 288(33.1) 162(18.6) 126(14.4) 
35-44 190(21.8) 108(12.4) 82(9.4) 
45-54 89(10.2) 108(12.4) 36(4.1)  
55-64 54(6.2) 29(3.3)  25(2.9)  
> 64 48(5.5) 25(2.9)  23(2.6)  
Total 872(100) 479(54.9) 393(45.1) 
 
A total of 695 (79.7%) of the 872 clients requested to 
join the study accepted HIV testing, and 39.1% 
(272/695) were sero-positive.   Females constituted 
44.9% (312/695) of which 43.9% (137/312) being 
sero-positive.  Males constituted 55.1% (388/695), 
with 34.8% (135/388) being infected.  Overall females 
constituted 50.7% and males 48.3% of the HIV cases.   
There was a significant difference in HIV infection rate 
between gender, females being more vulnerable [OR = 
0.695; 95% CI: 0.512-0.945; P = 0.020].  The majority 
(39.3%) of the HIV cases were in the 25-34 age-group 
followed by the 35-44 (24.6%) and 15-24 (15.8%) age-
groups respectively.  The 0-14 year age-group had 
2.9% if the HIV cases (Table 2).  Only 16.9% (46/272) 
of the HIV/AIDS cases were on antiretroviral therapy 
(ART), 65.2% females and 34.8% males. 
 
Table 2.  HIV and gender-age distribution 
Age-group N (%) Males (%) Females (%) OR 95%CI P-value 
0-14 8(2.9) 3(1.1) 5(1.8) 0.215 0.032-1.411 0.109 
15-24 43(15.8) 21(7.7) 22(8.1) 0.752 0.360-1.570 0.447 
25-34 107(39.3) 53(19.5) 54(19.9) 0.707 0.422-1.834 0.187 
35-44 67(24.6) 32(11.8) 35(12.9) 0.549 0.288-1.047 0.068 
45-54 24(8.8) 12(4.4) 12(4.4) 0.533 0.195-1.456 0.220 
55-64 14(5.1) 10(3.7) 4(1.5) 3.864 0.967-15.443 0.056 
> 64 9(3.3) 4(1.5) 5(1.8) 0.518 0.114-2.362 0.395 
Total 272(100) 135(49.6) 137(50.4) 0.695 0.512-0.945 0.020 
 
Discussion 
The HIV/AIDS and associated tuberculosis (TB) are 
robbing many countries of resources and capacities on 
which human security and development depend.  
Dozens of resource-poor countries are already in the 
grip of serious epidemics [10]. Tuberculosis is the most 
common opportunistic infection in HIV/AIDS patients, 
and the commonest cause of hospitalization and death 
in HIV/AIDS patients [11]. Although overall national 
HIV/AIDS prevalence in Kenya has shown a steady 
decline [6], the scourge continues to afflict the youth 
and young adults and the poor.  This report (2007 
national survey) indicates the national HIV prevalence 
among the 14-49 age bracket to be between 8-9% in 
the urban areas and 6-7% in the rural areas.  This gave 
a national combined prevalence of 7.5%.  This is in 
agreement with the present study in which close to 
80% of the HIV infections were in the 15-44 year age-
group.  However, the high overall HIV prevalence 
(39.1%) in present study could be attributed to the 
study having been done among high risk groups.  The 
HIV prevalence is higher among TB cases compared to 
the general population, and is currently the greatest risk 
factor for the progression of latent TB infection to 
active TB, and rapid progression of new TB infection.  
It is also a potential risk for recurrence of TB [11, 12].  
However, high HIV prevalence reported in this study is 
comparable with the 2007, 2008 and 2009 DLTLD 
annual reports give co-infection prevalence rates of 
48%, 45% and 44%, respectively [13, 14, 15]. 
The National Aids Control Council/National AIDS and 
STDs Control Programme (NACC/NASCOP) [6] in 
the 2007 survey reports males to constitute about 
41.4% (570947/1377472) of the cases compared to 
females (58.6%).  The HIV sero-prevalence was 3.7%, 
and 6.7% among males and females respectively.  In 
the present study, the HIV sero-prevalence in males 
was 34.8% compared to 43.9% in females is fairly in 
agreement with the NACC/NASCOP [6] report, which 
is in agreement with the NACC/NASCOP report, in 
terms of females being more vulnerable.  The plausible 
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explanation for the higher rates of HIV infection 
observed in this study could be attributed to the study 
having been done among high risk groups.  This study 
shows that majority (64%) of the HIV infected cases 
were in the 25-44 age-group, the most productive 
group in the community.  Since HIV infected 
individuals are more vulnerable to TB infection in 
high-burden countries like Kenya, this will undermine 
the small gains in economic development that has been 
achieved.  By affecting the 25-44 age-group so heavily, 
HIV/AIDS is not only hitting adults in their most 
economically productive years, but also removing the 
very people who could be responding to the HIV/AIDS 
crisis [16], meaning that HIV/AIDS will continue to 
adversely affect socio-economic development in 
resource-poor countries for many years to come. 
Stigma associated with HIV/AIDS infection continues 
to be an impediment to the war against HIV/AIDS as 
evidenced by 20.3% of candidates declining to undergo 
HIV testing in the present study.  The non-consenting 
population was represented across all the age-groups 
except the 0-14 age-group, where the guardians 
assented the HIV test.  Fear of discrimination often 
prevents people from getting tested, seeking treatment 
and admitting their HIV status publicly.  Many 
countries have legislated laws and policies against 
discrimination, but this alone cannot reverse the stigma 
that surrounds HIV infection.  HIV/AIDS education in 
Africa needs to be scaled-up to combat the ignorance 
that causes people to discriminate. The fear and 
prejudice that lies at the core of HIV and AIDS 
discrimination needs to be tackled at both community 
and national levels [16, 17]. Only 16.9% (46/272) of 
the HIV cases were on antiretroviral therapy (ART), 
65.2% females and 34.8% males.  However, the 
number of HIV cases needing to be put on ART could 
not be established in the present study.  Nationally, 
however, of the 1.4 million Kenyans infected with 
HIV, about 42.6% (243,000/570,000) of those needing 
ART are on ARVs [18].  This means that Universal 
Access to ART in Kenya remains a big challenge.  
 
Conclusion 
The HIV/AIDS continues to predominantly affect 
young adult Kenyans in their most productive years of 
life.  Almost three decades into the HIV/AIDS 
epidemic, much more effort needs to be directed to 
prevention of new HIV infections among the youth and 
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